| Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer H Yang, B Higgins, K Kolinsky, K Packman, WD Bradley, RJ Lee, ... Cancer Research 72 (3), 779-789, 2012 | 252 | 2012 |
| Regulation of cell migration and morphogenesis by Abl-family kinases: emerging mechanisms and physiological contexts WD Bradley, AJ Koleske Journal of cell science 122 (19), 3441-3454, 2009 | 230 | 2009 |
| Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation F Su, WD Bradley, Q Wang, H Yang, L Xu, B Higgins, K Kolinsky, ... Cancer Research 72 (4), 969-978, 2012 | 212 | 2012 |
| EZH2 inhibitor efficacy in non-Hodgkin’s lymphoma does not require suppression of H3K27 monomethylation WD Bradley, S Arora, J Busby, S Balasubramanian, VS Gehling, ... Chemistry & biology 21 (11), 1463-1475, 2014 | 164 | 2014 |
| Integrin signaling through Arg activates p190RhoGAP by promoting its binding to p120RasGAP and recruitment to the membrane WD Bradley, SE Hernández, J Settleman, AJ Koleske Molecular biology of the cell 17 (11), 4827-4836, 2006 | 163 | 2006 |
| Inhibition of Rho via Arg and p190RhoGAP in the postnatal mouse hippocampus regulates dendritic spine maturation, synapse and dendrite stability, and behavior MK Sfakianos, A Eisman, SL Gourley, WD Bradley, AJ Scheetz, ... Journal of Neuroscience 27 (41), 10982-10992, 2007 | 137 | 2007 |
| The Abl-related gene tyrosine kinase acts through p190RhoGAP to inhibit actomyosin contractility and regulate focal adhesion dynamics upon adhesion to fibronectin JG Peacock, AL Miller, WD Bradley, OC Rodriguez, DJ Webb, AJ Koleske Molecular biology of the cell 18 (10), 3860-3872, 2007 | 118 | 2007 |
| Integrin β1 signals through Arg to regulate postnatal dendritic arborization, synapse density, and behavior MS Warren, WD Bradley, SL Gourley, YC Lin, MA Simpson, LF Reichardt, ... Journal of Neuroscience 32 (8), 2824-2834, 2012 | 117 | 2012 |
| Direct interactions with the integrin β1 cytoplasmic tail activate the Abl2/Arg kinase MA Simpson, WD Bradley, D Harburger, M Parsons, DA Calderwood, ... Journal of Biological Chemistry 290 (13), 8360-8372, 2015 | 47 | 2015 |
| Mechanism of action of a novel viral mutagenic covert nucleotide: molecular interactions with HIV-1 reverse transcriptase and host cell DNA polymerases E Murakami, A Basavapathruni, WD Bradley, KS Anderson Antiviral research 67 (1), 10-17, 2005 | 40 | 2005 |
| Optimizing the interfacial binding and activity of a bacterial phosphatidylinositol-specific phospholipase C J Feng, WD Bradley, MF Roberts Journal of Biological Chemistry 278 (27), 24651, 2003 | 37 | 2003 |
| A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas W Harb, J Abramson, M Lunning, A Goy, K Maddocks, C Lebedinsky, ... Annals of Oncology 29, iii7, 2018 | 30 | 2018 |
| The emerging role of the intestine in metabolic diseases WD Bradley, C Zwingelstein, CM Rondinone Archives of physiology and biochemistry 117 (3), 165-176, 2011 | 29 | 2011 |
| Design, synthesis, and pharmacological evaluation of second generation EZH2 inhibitors with long residence time A Khanna, A Côté, S Arora, L Moine, VS Gehling, J Brenneman, ... ACS Medicinal Chemistry Letters 11 (6), 1205-1212, 2020 | 24 | 2020 |
| A phase 1b/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration … ME Taplin, A Hussain, ND Shore, B Bradley, P Trojer, C Lebedinsky, ... Journal of Clinical Oncology 36 (6_suppl), TPS398-TPS398, 2018 | 16 | 2018 |
| ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic … ME Taplin, A Hussain, S Shah, ND Shore, M Agrawal, W Clark, ... Journal of Clinical Oncology 37 (7_suppl), TPS335-TPS335, 2019 | 13 | 2019 |
| Abstract CT094: Phase Ib results of ProSTAR: CPI-1205, EZH2 inhibitor, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration … ME Taplin, A Hussain, S Shah, ND Shore, WJ Edenfield, OA Sartor, ... Cancer research 79 (13_Supplement), CT094-CT094, 2019 | 12 | 2019 |
| First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers. RC Lynch, JC Bendell, RH Advani, GS Falchook, PN Munster, MR Patel, ... Journal of Clinical Oncology 39 (15_suppl), 3006-3006, 2021 | 6 | 2021 |
| Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors. RC Lynch, PN Munster, GS Falchook, ML Burness, TA Yap, G Shapiro, ... Journal of Clinical Oncology 41 (16_suppl), 3099-3099, 2023 | 1 | 2023 |
| Ezh2 inhibition in combination therapies for the treatment of cancers WD Bradley US Patent App. 17/628,948, 2022 | 1 | 2022 |
